188 related articles for article (PubMed ID: 31620844)
1. The new international neuroblastoma response criteria.
Orr KE; McHugh K
Pediatr Radiol; 2019 Oct; 49(11):1433-1440. PubMed ID: 31620844
[TBL] [Abstract][Full Text] [Related]
2. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR; Bagatell R; Cohn SL; Pearson AD; Villablanca JG; Berthold F; Burchill S; Boubaker A; McHugh K; Nuchtern JG; London WB; Seibel NL; Lindwasser OW; Maris JM; Brock P; Schleiermacher G; Ladenstein R; Matthay KK; Valteau-Couanet D
J Clin Oncol; 2017 Aug; 35(22):2580-2587. PubMed ID: 28471719
[TBL] [Abstract][Full Text] [Related]
3. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
4. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.
Matthay KK; Shulkin B; Ladenstein R; Michon J; Giammarile F; Lewington V; Pearson AD; Cohn SL
Br J Cancer; 2010 Apr; 102(9):1319-26. PubMed ID: 20424613
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
6. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
7. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.
Shulkin BL; Shapiro B; Hutchinson RJ
J Nucl Med; 1992 Oct; 33(10):1735-40. PubMed ID: 1403138
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the utility of
Gauguet JM; Pace-Emerson T; Grant FD; Shusterman S; DuBois SG; Frazier AL; Voss SD
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449267
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. 131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
El-Maghraby T
Gulf J Oncolog; 2007 Jul; (2):33-41. PubMed ID: 20084722
[TBL] [Abstract][Full Text] [Related]
11. Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans.
Gordon I; Peters AM; Gutman A; Morony S; Dicks-Mireaux C; Pritchard J
J Nucl Med; 1990 Feb; 31(2):129-34. PubMed ID: 2313350
[TBL] [Abstract][Full Text] [Related]
12. Diffuse bone marrow infiltration of a neuroblastoma mimicking the findings of a bone marrow scan on I-123 MIBG scintigraphy.
Grüning T; Kropp J; Franke WG
Clin Nucl Med; 2001 Dec; 26(12):1044. PubMed ID: 11711716
[No Abstract] [Full Text] [Related]
13. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma Presenting as Non-MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by FDG PET/CT Imaging.
Tolboom N; Servaes SE; Zhuang H
Clin Nucl Med; 2017 Aug; 42(8):643-644. PubMed ID: 28525450
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis, Treatment Response, and Prognosis: The Role of
Piccardo A; Morana G; Puntoni M; Campora S; Sorrentino S; Zucchetta P; Ugolini M; Conte M; Cistaro A; Ferrarazzo G; Pescetto M; Lattuada M; Bottoni G; Garaventa A; Giovanella L; Lopci E
J Nucl Med; 2020 Mar; 61(3):367-374. PubMed ID: 31541036
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M; Simon T; Hero B; Schicha H; Berthold F
Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
[TBL] [Abstract][Full Text] [Related]
18. Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor.
Zhang W; Zhuang H; Servaes S
Clin Nucl Med; 2016 Aug; 41(8):632-3. PubMed ID: 26825196
[TBL] [Abstract][Full Text] [Related]
19. Does I-131-MIBG underestimate skeletal disease burden in neuroblastoma?
Barai S; Bandopadhayaya GP; Malhotra A; Agarwal S; Kumar R; Dhanapathi H
J Postgrad Med; 2004; 50(4):257-60; discussion 260-1. PubMed ID: 15623965
[TBL] [Abstract][Full Text] [Related]
20. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
